Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials-Reference-Cited by-同舟云学术

Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials

Published:2023-08-01 Issue:4 Volume:34 Page:308-314
ISSN:1710-3568
Container-title:Dermatitis®
language:en
Short-container-title:Dermatitis®

Author:

Wollenberg Andreas¹²,Kircik Leon³,Simpson Eric⁴,Brinker Dennis⁵,Katoh Norito⁶,Rueda Maria Jose⁵,Issa Maher⁵,Yang Fan⁵,Feely Meghan⁵⁷,Alexis Andrew⁸

Affiliation:

1. From the Department of Dermatology and Allergy University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.

2. Department of Dermatology, Free University Brussels, University Hospital Brussels, Brussels, Belgium.

3. Icahn School of Medicine at Mount Sinai, New York, New York, USA.

4. Oregon Health & Science University, Portland, Oregon, USA.

5. Eli Lilly and Company, Indianapolis, Indiana, USA.

6. Department of Dermatology Kyoto Prefectural University of Medicine, Kyoto, Japan.

7. Icahn School of Medicine, Mount Sinai, New York, New York, USA.

8. Weill Cornell Dermatology, New York, New York, USA.

Publisher

Mary Ann Liebert Inc

Subject

Dermatology,Immunology and Allergy

Link

https://www.liebertpub.com/doi/pdf/10.1089/derm.2022.0027

Reference16 articles.

1. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies

2. Atopic dermatitis endotypes and implications for targeted therapeutics

3. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis

4. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder

5. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Janus Kinase Inhibitors as a Third-Line Therapy for Refractory Endogenous Noninfectious Uveitis;Ocular Immunology and Inflammation;2024-05-06

2. Self-Assessment;Dermatitis®;2023-08-01